Paul Tudor Jones Arcus Biosciences, Inc. Transaction History

Tudor Investment Corp Et Al

$26.8 Billion
Q3 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 45,650 shares of RCUS stock, worth $726,291. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,650

Holding current value

$726,291

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $624,948 - $822,156	45,650 New	45,650 $697,000
Q3 2023 Nov 15, 2023	BUY	$17.62 - $23.54 $496,408 - $663,192	28,173 New	28,173 $505,000
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $1.29 Million - $2 Million	-41,200 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $346,239 - $484,451	-12,857 Reduced 23.78%	41,200 $1.44 Million
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $1.06 Million - $1.67 Million	46,796 Added 644.48%	54,057 $1.48 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $740,223 - $1.17 Million	-28,296 Reduced 79.58%	7,261 $204,000
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $604,469 - $1.15 Million	35,557 New	35,557 $923,000
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $1.14 Million - $1.69 Million	-66,529 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $929,410 - $2.43 Million	66,529 New	66,529 $1.65 Million
Q1 2020 May 15, 2020	SELL	$8.78 - $19.28 $117,853 - $258,795	-13,423 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $98,390 - $144,834	13,423 New	13,423 $136,000
Q2 2018 Aug 14, 2018	SELL	$12.24 - $17.05 $339,329 - $472,677	-27,723 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$15.44 - $17.71 $428,043 - $490,974	27,723 New	27,723 $428,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.15B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account